{"id":"NCT02597049","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-02","completion":"2017-02","firstPosted":"2015-11-04","resultsPosted":"2018-04-27","lastUpdate":"2020-06-17"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dulaglutide","otherNames":["LY2189265"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SGLT2 inhibitor","otherNames":["Canagliflozin","Dapagliflozin","Empagliflozin"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"1.5 mg Dulaglutide","type":"EXPERIMENTAL"},{"label":"0.75 mg Dulaglutide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"1.5 mg Dulaglutide","deltaMin":-1.34,"sd":0.064},{"arm":"0.75 mg Dulaglutide","deltaMin":-1.21,"sd":0.064},{"arm":"Placebo","deltaMin":-0.54,"sd":0.064}],"pValues":[{"comp":"OG000 vs OG002","p":"<.001"},{"comp":"OG001 vs OG002","p":"< .001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":41,"countries":["United States","Austria","Czechia","Germany","Hungary","Israel","Mexico","Puerto Rico","Spain"]},"refs":{"pmids":["36894938","29483060"],"seeAlso":["http://www.lillytrialguide.com/EN-US/studies/diabetes/gbge"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":142},"commonTop":["Back pain","Nausea","Viral upper respiratory tract infection","Diarrhoea","Headache"]}}